x 

0 Activities
0 Activities
    • No Saved Activities
Page 2 of 2
Results 151 - 274 of 274
No image set
Understanding Lysosomal Storage Disorders
No image set
hATTR Amyloidosis: You and Your Family
No image set
The SLE Consult: Diagnosis, Treatment Selection, Treatment Targets, and Monitoring
No image set
The SLE Consult: Lupus Nephritis, Patient-Clinician Communication, and Treatment Adherence
9165 product
Utilizing ACIP's Updated Pneumococcal Recommendations - Rapid Recap
No image set
Applying Principles of Pain Management
No image set
Patient Case: Osteoarthritis (OA) of the Knee
No image set
Patient Case: Lower Back Pain
No image set
Managing the Whole Patient with COPD: An Animated Video Series
No image set
Advances in Multiple Sclerosis (AIMS) Primer: 3rd Edition
No image set
A Practical Guide to Rehabilitation in Multiple Sclerosis: 2nd Edition
No image set
My COPD Action Plan
No image set
Expert Recommendations for COPD
No image set
Lipids: Successful Co-management between Primary Care and Endocrinology
No image set
Bone/Thyroid: Successful Co-management between Primary Care and Endocrinology
No image set
Obesity: Successful Co-management between Primary Care and Endocrinology
No image set
Diabetes: Successful Co-management between Primary Care and Endocrinology
No image set
SMA Updates from Around the World
9920-0004-conf_covg_icon_263x149
Updates in SMA from Charlotte, North Carolina
No image set
Surgical and Minimally Invasive Procedures that Might Benefit COPD Patients
No image set
COPD: Fixed Dose Combinations
No image set
COPD: Proper Inhaler Use
No image set
Technology Improving SMA Patients’ Quality of Life
No image set
Nusinersen Treatment Outcomes in Later-Onset SMA
No image set
Patients with Severe SMA Need Additional Respiratory Management
Castro_02
Clear Expectations Needed in SMA Patient Management
Castro_01
Improvements in Quality of Life for Patients with Neuromuscular Diseases
9920-264x150
The Changing Landscape of SMA–Updates from Copenhagen, Denmark
No image set
Interstitial Pneumonia with Autoimmune Features (IPAF)
No image set
How to Identify & Manage Patients with Progressive-Fibrosing ILD
No image set
A Step-by-Step Guide to Diagnosing SLE in the Primary Care Setting
9840-0004-icon
Acute Exacerbations of IPF
9916-cme-icon
Personalized Medicine for Improving Asthma Care: An Animated Video Series
9815-developments
New Developments in Pulmonary Diseases: Optimizing Patient Outcomes
9815-palliative slides
Palliative Medicine in Pulmonology
9916-0005-icon
Discussions with Patients to Optimize Asthma Control
9916-0004_treatment
Who Should be Targeted For Treatment With Biologic Therapy?
9916-0003_endotypes
Endotypes and Phenotypes in Asthma
9916-0002_moa3
Mechanisms of Action of Biologic Therapies for Severe Asthma
9916-0001_meds
Approved Medications for the Treatment of Severe Asthma
9907-0006_shared
Engage Your Patients in Shared Decision-Making
9907-0005_cardio
Is It IPF or Cardiovascular Disease?
9907-0004_ip
Interstitial Pneumonia with Autoimmune Features
9907-0003_pf-ild
How to Identify Progressive Fibrosing ILD
9907-0002_ctd
When Is It a Connective Tissue Disease?
9907-0001_guidelines
How to Use IPF Guidelines to Make a Diagnosis
9916-kalluri
Advanced Care Planning and Palliative Care Models for Patients with IPF
9916-kalluri
Dyspnea Assessment in Patients with IPF
9916-scholand1
Which Patients with IPF Should be on Antifibrotics?
9916-brown5
The Impact of Anticoagulation Use on IPF Patient Outcomes
9916-brown5
Patient-Centered Outcomes for Patients with IPF: Activity Monitoring
9916-solomon
Connective Tissue Disease-Related ILD is Now in the Limelight
9916-brown5
Biomarkers in IPF and Other ILDs
9840-glassberg2
Evaluation and Diagnosis of IPF
9840-glassberg1
Initial Treatment Decisions of IPF
curesma19-icon
The Changing Landscape of SMA–Updates from Anaheim, CA
9837-coolidge
What if President Calvin Coolidge Was Your Asthma Patient?
9840-0003
Optimizing Management of IPF
New_Concepts_in_the_Pathobiology_of_Asthma_264x150
New Concepts in the Pathobiology of Asthma
9916-king
What are the Most Exciting Things Happening in Pulmonary Disease?
9837-roosevelt
How Would You Manage President Theodore Roosevelt’s Asthma Today?
9916-scholand
New Tools to Improve the Diagnosis of IPF vs Other ILDs
9916-brown
New Research on Therapies for Patients with Pulmonary Fibrosis
9916-richeldi
The SENSCIS Trial: Exciting News for Scleroderma-Associated ILD
9916-cc-cme
2019 Summer Pulmonary Updates: The Experts Weigh In
med-doc-aatd
A Closer Look at Alpha-1 Antitrypsin Deficiency: Peggy’s Story
med-doc-ph
How Pulmonary Arterial Hypertension Has Changed Iain’s Life
hopa-icon8
Biosimilars: Applying the Science to Hematology/Oncology Practice
9816-0001
The Latest from a Recent Pulmonary Conference in San Antonio
9816-0010
Updates in Inoperable CTEPH
9816-0009
The Importance of Early Integration of Palliative Care
9816-0006
Management of IPF Patients in 2018
9816-0005
Updates in the Diagnosis of ILD and the Role of Cryobiopsy
9816-00045
Overview of the Latest Clinical Trials in IPF
9816-0003
Evolution of Antifibrotic Therapy in IPF
9816-0002
Take Home Messages from the 2018 CHEST Annual Meeting
9816-0008
What We’re Learning from the IPF-PRO Registry
9816-0007
Comparing the 2017 Fleischner Society Guidelines and the 2018 ATS Guidelines
atopic-derm4
Atopic Dermatitis: Putting it Together (Dermatology)
atopic-derm3
Atopic Dermatitis: Putting it Together (Primary Care)
atopic-derm2 copy
Atopic Dermatitis: Recent and Emerging Therapies
atopic-derm1
An Introduction to Atopic Dermatitis
asthma-uncontrol icon
A Personalized Approach to Managing Uncontrolled Asthma
Proper_Use_of_an_Inhaler_264x150
Proper Use of an Inhaler
psoriasis-nurse
Psoriasis Management Considerations: What Would You Do?
psoriasis-case3
Jamie Develops Complications with Her Psoriasis
psoriasis-case2
Psoriasis: Three Case Studies in the Primary Care Setting
psoriasis-case1
Cindy Has a Complex Case of Psoriasis
9707-ella
Famous People with Diabetes: Ella Fitzgerald
9707-jerry
Famous People with Diabetes: Jerry Garcia
aims icon-target
Targeting B-cells in Primary Progressive MS (PPMS)
aims icon-comorb
Comorbidities and Selection of DMTs
aims icon-gut
The Gut Microbiota in MS
aims icon-early
Early MS: Induction Therapy and Escalation Strategies
aims icon-vitamin
Vitamin D: Modifiable Risk Factor and its Role in the Management of Patients with MS
t2diabetes-slides1
Download Slides: Optimizing Diabetes Treatment in a Sea of Treatment Options
No image set
The Importance of Early Referral and Treatment
No image set
How to Recognize and Diagnose IPF
No image set
What Is IPF?
t2diabetes-slides2
Download Slides: Advancing T2DM Therapy with Confidence
t2diabetes-louise
Getting to Goal Can Be Difficult: Louise
t2diabetes-brian
Getting to Goal Can Be Difficult: Brian
IL-rheum-case3
Considering Biosimilars in Patients Failing their Initial Biologic
IL-rheum-case2
When to Switch? Biologically Experienced Patients with Spondyloarthritis
IL-rheum-case1
Innovator or Biosimilar for a Patient with Rheumatoid Arthritis
IL-gastro-case3
Ulcerative Colitis: What Can You Expect When a Patient is Switched to a Biosimilar?
IL-gastro-case2
Biosimilars in Patients with Crohn’s Disease Failing an Initial Biologic
IL-gastro-case1
Innovator or Biosimilar for a Patient with Ulcerative Colitis?
IL-derm-case3
Switching Between Biologics: Is a Biosimilar an Option?
IL-derm-case2
When to Switch? Biologically Experienced Psoriasis Patients
IL-derm-case1
Innovator or Biosimilar for a Patient with Psoriasis
IL-fund-case4
Interchangeability and Pharmacy-Level Substitution
IL-fund-case3
FDA Criteria: Biosimilar Approval, Manufacturing, & Naming
IL-fund-case2
What is the Difference Between a Biosimilar and a Generic?
biosims-full
Sorting it Out: Biologics, Biosimilars, Small Molecule Drugs, and Generics
biosims-green5
Are You Ready to Use Biosimilars in Your Practice?
biosims-full3
Health Care Providers’ Perspectives on Biosimilars: Based in Fact or Not?
biosims-green3
Pharmacovigilance and Biosimilars: Any Special Considerations?
biosims-full5
Interchangeability and Biosimilars: What will this Mean for Clinical Practice?
biosims-green8
Can a Biosimilar be Used for the Same Indications Approved for the Reference Biologic?
biosims-full7
Biosimilars: As Safe and Effective as the Reference Product?
biosims-green
Drift and the Manufacturing of Biologics: What is it and Does it Matter?
biosims-full8
Biosimilars in Clinical Practice: Interchangeability and Extrapolation
No image set
Addressing Common Barriers to Adherence
Page 2 of 2

Search